References
http://www.marketwatch.com/story/at-one-month-post-launch-over-half-of-surveyed-us-neurologists-have-prescribed-biogen-idecs-tecfidera-the-third-to-market-oral-therapy-to-their-multiple-sclerosis-patients-2013-07-11. Accessed September 4, 2013
Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097
Gold R, Kappos L, Arnold DL et al (2012) DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107
Kappos L, Gold R, Miller DH et al (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648):1463–1472
http://www.tecfidera.com/pdfs/full-prescribing-information.pdf. Accessed September 4, 2013
Conflicts of interest
Dr. Ratchford’s spouse has consulted for Biogen-Idec, CDMI, Diogenix, and Genzyme, and receives research funding for clinical trials from Biogen-Idec, Novartis, and Sun Pharmaceuticals. J. Todd Baldanza: none. Dr. Pardo receives research funding from Project Restore and The Bart McLean Fund for Neuroimmunology Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ratchford, E.V., Baldanza, J.T. & Pardo, C.A. Extensive bilateral lower extremity deep venous thrombosis in a patient on dimethyl fumarate. J Neurol 261, 831–832 (2014). https://doi.org/10.1007/s00415-014-7288-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-014-7288-9